Investigating the role of symptom valorisation in tuberculosis patient delay in urban areas in Portugal
Margarida de Morais(National School of Public Health), Carlos Carvalho(European Centre for Disease Prevention and Control), Maria Célia Mendes, Maria Fernanda Teixeira, Lucinda Silva, Márcia Cardoso(Terumo (Belgium)), Maria Inês Gameiro(Universidade do Porto), Sofia S. Pereira(Unidade Local de Saúde de São José), Marta Moniz(Universidade Nova de Lisboa), Jorge Gonçalves(University of Luxembourg), Marta Lopes(Universidade do Porto), Ana Paula Rodrigues(Microsoft (Brazil)), Ana Marta Gomes(Unidade Local de Saúde de São José), Ana Sofia Moreira, Maria do Carmo Pereira(Universidade do Porto), Sofia Sousa(Universidade do Porto), Manuel R. Pereira, Isabel Correia(Universidade Federal de Minas Gerais), Andreia Leite(National School of Public Health), Sandra Mota(Unidade Local de Saúde de São José), Patrícia Soares(National Institute of Health Dr. Ricardo Jorge), Filipe Alves(Madeira Tecnopolo), Adriana Távora de Albuquerque Taveira, Milena Piedade(Centro Hospitalar de Vila Nova de Gaia), Antónia Teixeira(Hospital de São João), L. Ferreira(Universidade Nova de Lisboa), Catarina Magalhães Alves, Ângela Dias, Celene Neves, Anabela Susana de Sousa Gonçalves(Karlsruhe Institute of Technology), Mário Carreira(Universidade do Porto), Juan Rachadell, Jéssica Marques(Universidade Nova de Lisboa), Raquel Duarte(Universidade do Porto)
Cited by 3
Related Papers
Excess all-cause mortality during the COVID-19 pandemic in Europe – preliminary pooled estimates from the EuroMOMO network, March to April 2020
|Eurosurveillance|2020|238
MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network
|International Journal of Infectious Diseases|2020|226
The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century
|PLoS ONE|2019|185
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
|European Respiratory Journal|2019|176
Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer’s disease treatment
|Colloids and Surfaces B Biointerfaces|2016|175